Experimental colon cancer drug may delay progression, improve overall survival.
Dow Jones Newswire (1/25, Solsman) reported that, according to Keryx Biopharmaceuticals Inc., a midstage trial of patients with advanced colon cancer showed that its experimental cancer drug, KRX-0401, or perifosine, helped delay disease progression and improve overall survival. When given in combination with capecitabine, the drug also increased the percentage of participants with stable disease for two weeks or longer.
Reuters (1/25) reported, however, that patients also experienced a higher incidence of adverse events, including anemia and hand-foot syndrome.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment